Research About Impact of HPV Integration on the Prognosis of Women With Persistent HR-HPV Infection

Launched by FUJIAN MATERNITY AND CHILD HEALTH HOSPITAL · Mar 7, 2022

Keywords

ClinConnect Summary

This clinical trial is studying how the integration of the human papillomavirus (HPV) into cells affects the health outcomes of women who have a persistent high-risk HPV infection. Researchers are looking at 1,000 women who have had the same type of high-risk HPV for over 18 months or have certain cervical changes (CIN2 or higher). They will assess these women's HPV status and the diversity of their vaginal bacteria at different times over two years to see how these factors influence their health.

To participate, women must be non-pregnant and have a history of sexual activity. They should have had a persistent HPV infection for more than 18 months or have been diagnosed with CIN2 or higher. Women with previous cervical surgeries, recent infections, or those who have had HPV vaccinations are not eligible. Participants can expect to undergo regular health assessments and tests over two years, helping researchers understand how HPV integration impacts their condition. This information could be crucial in improving care for women with persistent HPV infections.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • Non pregnant people with sexual history；
• • Persistent infection of the same type of HR-HPV for more than 18 months or HR-HPV infection with CIN2 +;
• • No history of previous surgery at the cervical site.
• • Asexual life, no vaginal medication or flushing before 72 hours of sampling.
• Exclusion Criteria:
• • Within 8 weeks after pregnancy or postpartum.
• • Patients with history of genital tract tumor.
• • History of HPV vaccination.
• • Previous history of hysterectomy, cervical surgery, pelvic radiotherapy Historical.
• • In recent one month, she has received genital tract infection, HPV or other STDs treatment related to the infection of mycoplasma.
• • Use antibiotics or vaginal microecological improvement products in recent 1 month.